Clinical trials: Hypomethylating Agents
Myelodysplastic Syndromes, Dendritic Cell
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology.
- Conditions
- Myelodysplastic Syndromes, Dendritic Cell, Hypomethylating Agents, Immunotherapy
- Trial name
- eDC-MDS (NCT04999943)
- Testing
- DC vaccine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic…
- Conditions
- Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT03896269
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML), CEBPA Mutation
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
The goal of this clinical trial is to learn if a treatment combination-venetoclax plus hypomethylating agents (like azacitidine or decitabine) and low-dose cytarabine-works to treat adults with newly diagnosed CEBPA-mutated acute…
- Conditions
- Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML
- Trial name
- NCT07451912
- Testing
- Venetoclax + Hypomethylating Agents + Low-Dose Cytarabine for CEBPA-Mutated AML (Unfit Patients)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Soochow University
MDS, Myelodysplastic Syndromes
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
The purpose of this study is to evaluate the effect of Romiplostim (AMG 531) on the incidence of clinically significant thrombocytopenic events (grade 3 or 4 and/or receipt of platelet transfusions) in subjects with low or…
- Conditions
- MDS, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00321711
- Testing
- AMG 531 (Romiplostim), Azacitidine, Decitabine
- Volunteers
- 69 people
- Sponsor
- Amgen
Myelodysplastic Syndromes
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents
The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response, and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment.
- Trial name
- NCT01246076
- Testing
- Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia
Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy
This single-arm interventional study evaluated the short-term outcome of one 28-day cycle of venetoclax combined with a hypomethylating agent (azacitidine or decitabine) in adults with newly diagnosed acute myeloid leukemia who…
- Trial name
- NCT07773909
- Testing
- Venetoclax, Azacitidine, Decitabine
- Where
- Bangladesh
- Volunteers
- 24 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Myelodysplastic Syndrome (MDS)
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral…
- Trial name
- NCT04878432
- Testing
- MBG453, Azacitidine, Decitabine
- Where
- 15 sites in United States
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation
HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT
Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long-term survivors of allo-HSCT.
- Trial name
- NCT03662087
- Testing
- HMA+DLI, DLI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelodysplastic Syndrome
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome
This is a Phase II study to evaluate the efficacy of second-line lenalidomide monotherapy for myelodysplastic syndrome (MDS) patients who failed to hypomethylating agents.
- Trial name
- VIOLET (NCT01673308)
- Testing
- Lenalidomide
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Ulsan University Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US
The study aims to comprehensively analyze data from a large and unselected older AML population in the US, both treated and untreated.
- Trial name
- NCT02863458
- Where
- United States
- Sponsor
- The Cleveland Clinic
Myelodysplastic Syndrome
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome…
- Trial name
- NCT02117219
- Testing
- MEDI4736 Evaluate MEDI4736 in MDS, VIDAZA, tremelimumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 67 people
- Sponsor
- MedImmune LLC
Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, and/or MPN. The safety of the drug combination will also be studied.
- Conditions
- Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms, IDH1-mutated Higher-Risk Myelodysplastic Syndromes
- Trial name
- NCT06597734
- Testing
- Olutasidenib
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Registry on Hypomethylating Agents in Myeloid Neoplasms
This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia
- Trial name
- NCT01595295
- Testing
- non interventional
- Where
- 20 sites in Austria, Croatia
- Volunteers
- 1,500 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Myelodysplastic Syndromes
CPX-351 in Higher Risk Myelodysplastic Syndromes
Study of the efficacy of CPX-351 treatment in patients with higher risk myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure
- Trial name
- NCT04273802
- Testing
- CPX-351 in cohort A, CPX-351 in cohort B
- Where
- 16 sites in France
- Volunteers
- 40 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Myelodysplastic Syndrome
Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
This phase Ib trial studies the side effects and best dose of entinostat when given together with pembrolizumab in treating patients with myelodysplastic syndrome after deoxyribonucleic acid (DNA) methyltransferase inhibitor…
- Trial name
- NCT02936752
- Testing
- Entinostat, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
This is a multicenter, prospective, translational study, to evaluate the immunogenic profile of AML cases according to immune checkpoint molecule expression.
- Trial name
- Immune-AML (NCT03789981)
- Testing
- Immunogenic profile
- Where
- 14 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Myelodysplastic Syndrome (MDS), Thrombocytopenia
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
The purpose of this study is to evaluate the safety and efficacy of eltrombopag in people who have myelodysplastic syndrome (MDS) with thrombocytopenia who have progressed or are resistant to decitabine or azacitidine.
- Trial name
- NCT01286038
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Myelodysplastic Syndrome, Myelodysplastic Syndromes
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
This is a Phase I/II, open-label, 2 arm study to evaluate the safety and clinical activity of GSK2879552 alone, or in combination with azacitidine in subjects with MDS. The study consisted of 2 parts.
- Trial name
- NCT02929498
- Testing
- GSK2879552, Azacitidine
- Where
- 6 sites in United States, Spain
- Volunteers
- 7 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
- Trial name
- NCT02732184
- Testing
- Co-ArgI-PEG modified human arginase I
- Where
- 10 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Immedica Pharma AB